{"id":"hydromorphone-er","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Headache"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydromorphone is a semi-synthetic opioid that activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. The extended-release formulation provides sustained drug delivery over 24 hours, allowing for once or twice-daily dosing in chronic pain management. It is approximately 6-8 times more potent than morphine.","oneSentence":"Hydromorphone ER is an opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:34.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain requiring continuous opioid therapy"},{"name":"Moderate to severe pain in opioid-tolerant patients"}]},"trialDetails":[{"nctId":"NCT04018664","phase":"PHASE1","title":"Oral Abuse Potential Study of Nalbuphine","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2018-05-29","conditions":"Nalbuphine, Opioid Abuse","enrollment":56},{"nctId":"NCT01892709","phase":"PHASE4","title":"Titration of Intravenous Hydromorphone","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2013-06","conditions":"Acute Severe Pain","enrollment":215},{"nctId":"NCT02601027","phase":"PHASE3","title":"Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-11","conditions":"Breast - Female","enrollment":120},{"nctId":"NCT04033094","phase":"","title":"Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-10-16","conditions":"Baseline Epidemiologic Assessment","enrollment":17566},{"nctId":"NCT02321319","phase":"PHASE3","title":"Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2017-03-11","conditions":"Chronic Pain","enrollment":5},{"nctId":"NCT01455519","phase":"PHASE4","title":"True Functional Restoration and Analgesia in Non-Radicular Low Back Pain","status":"COMPLETED","sponsor":"Shirley Ryan AbilityLab","startDate":"2011-10","conditions":"Low Back Pain","enrollment":51},{"nctId":"NCT00955110","phase":"PHASE4","title":"Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2009-06","conditions":"Healthy","enrollment":78},{"nctId":"NCT02920762","phase":"","title":"Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers","status":"UNKNOWN","sponsor":"ER/LA Opioid REMS Program Companies (RPC)","startDate":"","conditions":"Opioid Related Disorders, Opiate Addiction, Narcotic Abuse","enrollment":5575834}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DECREASED APPETITE"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"GLOSSODYNIA"},{"count":2,"reaction":"HYPOTENSION"},{"count":2,"reaction":"INFECTION"},{"count":2,"reaction":"NEUROPATHY PERIPHERAL"},{"count":2,"reaction":"PAIN"},{"count":2,"reaction":"PLASMA CELL MYELOMA"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Exalgo(hydromorphone HCl), CII (77605306)","Dilaudid"],"phase":"marketed","status":"active","brandName":"Hydromorphone ER","genericName":"Hydromorphone ER","companyName":"Shirley Ryan AbilityLab","companyId":"shirley-ryan-abilitylab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydromorphone ER is a small molecule medication used to treat acute severe pain. It is administered orally in extended-release form.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}